GRK2 at the control shaft of cellular metabolism

Current Pharmaceutical Design

Volumn 18, Issue 2, 2012, Pages 121-127

  Ciccarelli, Michele ^a   Cipolletta, Ersilia ^a   Iaccarino, Guido ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

Chronic disease; Glucose; Insulin signaling; Metabolism

Indexed keywords

G PROTEIN COUPLED RECEPTOR KINASE 2; GLUCOSE TRANSPORTER 4; INSULIN;

ALZHEIMER DISEASE; ARTICLE; CELL MEMBRANE; CELL METABOLISM; CHRONIC DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME REGULATION; GENE OVEREXPRESSION; GLUCOSE METABOLISM; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE INJURY; HUMAN; IMMUNOREACTIVITY; MUSCLE CELL; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; G-PROTEIN-COUPLED RECEPTOR KINASE 2; GLUCOSE; HEART FAILURE; HUMANS; INSULIN; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84856427725     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799040493     Document Type: Article

References (82)

1. Inglese J, Freedman NJ, Koch WJ, Lefkowitz RJ. Structure and mechanism of the G protein-coupled receptor kinases. J Biol Chem 1993; 268: 23735-8.
2. Krupnick JG, Benovic J L. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 1998; 38: 289-319.
3. Lefkowitz R J. G protein-coupled receptor kinases. Cell 1993; 74: 409-12.
4. Pierce KL, Premont RT, Lefkowitz R J. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002; 3: 639-50.
5. Koch WJ, Lefkowitz R J, Rockman HA. Functional consequences of altering myocardial adrenergic receptor signaling. Annu Rev Physiol 2000; 62: 237-60.
6. Brodde OE. Beta 1-and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991; 43: 203-42.
7. Freedman NJ, Liggett SB, Drachman DE, Pei G, Caron MG, Lefkowitz R J. Phosphorylation and desensitization of the human beta 1-adrenergic receptor. Involvement of G protein-coupled receptor kinases and cAMP-dependent protein kinase. J Biol Chem 1995; 270: 17953-61.
8. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. Faseb J 1990; 4: 2881-9.
9. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002; 115: 455-65.
10. Gros R, Benovic JL, Tan CM, Feldman RD. G-protein-coupled receptor kinase activity is increased in hypertension. J Clin Invest 1997; 99: 2087-93.
11. McDonald PH, Lefkowitz RJ. Beta-Arrestins: new roles in regulating heptahelical receptors' functions. Cell Signal 2001; 13: 683-9.
12. Pao CS, Benovic JL. Phosphorylation-independent desensitization of G protein-coupled receptors? Sci STKE 2002; 2002: pe42.
13. Ruiz-Gomez A, Humrich J, Murga C, Quitterer U, Lohse MJ, Mayor F Jr. Phosphorylation of phosducin and phosducin-like protein by G protein-coupled receptor kinase 2. J Biol Chem 2000; 275: 29724-30.
14. Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 2001; 294: 1307-13.
15. Carman CV, Lisanti MP, Benovic JL. Regulation of G proteincoupled receptor kinases by caveolin. J Biol Chem 1999; 274: 8858-64.
16. Carman CV, Parent JL, Day PW et al. Selective regulation of Galpha(q/11) by an RGS domain in the G protein-coupled receptor kinase, GRK2. J Biol Chem 1999; 274: 34483-92.
17. Sallese M, Mariggio S, D'Urbano E, Iacovelli L, De Blasi A. Selective regulation of Gq signaling by G protein-coupled receptor kinase 2: direct interaction of kinase N terminus with activated galphaq. Mol Pharmacol 2000; 57: 826-31.
18. DebBurman SK, Ptasienski J, Benovic JL, Hosey MM. G proteincoupled receptor kinase GRK2 is a phospholipid-dependent enzyme that can be conditionally activated by G protein betagamma subunits. J Biol Chem 1996; 271: 22552-62.
19. DebBurman SK, Ptasienski J, Boetticher E, Lomasney JW, Benovic JL, Hosey MM. Lipid-mediated regulation of G protein-coupled receptor kinases 2 and 3. J Biol Chem 1995; 270: 5742-7.
20. Manning BS, Shotwell K, Mao L, Rockman HA, Koch WJ. Physiological induction of a beta-adrenergic receptor kinase inhibitor transgene preserves ss-adrenergic responsiveness in pressureoverload cardiac hypertrophy. Circulation 2000; 102: 2751-7.
21. Rockman HA, Chien KR, Choi DJ et al. Expression of a betaadrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A 1998; 95: 7000-5.
22. Pronin AN, Carman CV, Benovic JL. Structure-function analysis of G protein-coupled receptor kinase-5. Role of the carboxyl terminus in kinase regulation. J Biol Chem 1998; 273: 31510-8.
23. Thiyagarajan MM, Stracquatanio RP, Pronin AN et al. A predicted amphipathic helix mediates plasma membrane localization of GRK5. J Biol Chem 2004; 279: 17989-95.
24. Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation 1993; 87: 454-63.
25. Ungerer M, Parruti G, Bohm M et al. Expression of beta-arrestins and beta-adrenergic receptor kinases in the failing human heart. Circ Res 1994; 74: 206-13.
26. Izzo R, Cipolletta E, Ciccarelli M et al. Enhanced GRK2 expression and desensitization of betaAR vasodilatation in hypertensive patients. Clin Transl Sci 2008; 1: 215-20.
27. Ungerer M, Kessebohm K, Kronsbein K, Lohse MJ, Richardt G. Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase. Circ Res 1996; 79: 455-60.
28. Choi D J, Koch WJ, Hunter JJ, Rockman HA. Molecular betaadrenergic signaling abnormalities in failing rabbit hearts after infarction. J Biol Chem 1997; 272: 17223-9.
29. Maurice JP, Shah AS, Kypson AP et al. Molecular beta-adrenergic signaling abnormalities in failing rabbit hearts after infarction. Am J Physiol 1999; 276: H1853-60.
30. Leosco D, Fortunato F, Rengo G. et al. Lymphocyte G-proteincoupled receptor kinase-2 is upregulated in patients with Alzheimer's disease. Neurosci Lett 2007; 415: 279-82.
31. Lombardi MS, Kavelaars A, Cobelens PM, Schmidt RE, Schedlowski M, Heijnen CJ. Adjuvant arthritis induces down-regulation of G protein-coupled receptor kinases in the immune system. J Immunol 2001; 166: 1635-40.
32. Mak JC, Chuang TT, Harris CA, Barnes PJ. Increased expression of G protein-coupled receptor kinases in cystic fibrosis lung. Eur J Pharmacol 2002; 436: 165-72.
33. Penela P, Barradas M, Alvarez-Dolado M, Munoz A, Mayor F Jr. Effect of hypothyroidism on G protein-coupled receptor kinase 2 expression levels in rat liver, lung, and heart. Endocrinology 2001; 142: 987-91.
34. Feldman RD. Deactivation of vasodilator responses by GRK2 overexpression: a mechanism or the mechanism for hypertension? Mol Pharmacol 2002; 61: 707-9.
35. Penela P, Alvarez-Dolado M, Munoz A, Mayor F Jr. Expression patterns of the regulatory proteins G protein-coupled receptor kinase 2 and beta-arrestin 1 during rat postnatal brain development: effect of hypothyroidism. Eur J Biochem 2000; 267: 4390-6.
36. Penela P, Ruiz-Gomez A, Castano JG, Mayor F Jr. Degradation of the G protein-coupled receptor kinase 2 by the proteasome pathway. J Biol Chem 1998; 273: 35238-44.
37. Penela P, Elorza A, Sarnago S, Mayor F Jr. Beta-arrestin-and c-Src-dependent degradation of G-protein-coupled receptor kinase 2. Embo J 2001; 20: 5129-38.
38. Salcedo A, Mayor F Jr, Penela P. Mdm2 is involved in the ubiquitination and degradation of G-protein-coupled receptor kinase 2. Embo J 2006; 25: 4752-62.
39. Garcia-Guerra L, Nieto-Vazquez I, Vila-Bedmar R et al. G proteincoupled receptor kinase 2 plays a relevant role in insulin resistance and obesity. Diabetes 2010; 59:2407-17.
40. Anis, Y.; Leshem, O.; Reuveni, H.; Wexler, I.; Ben Sasson, R.; Yahalom, B.; Laster, M.; Raz, I.; Ben Sasson S, Shafrir E, Ziv E. Antidiabetic effect of novel modulating peptides of G-proteincoupled kinase in experimental models of diabetes. Diabetologia 2004; 47: 1232-44.
41. Cipolletta E, Campanile A, Santulli G et al. The G protein coupled receptor kinase 2 plays an essential role in beta-adrenergic receptor-induced insulin resistance. Cardiovasc Res 2009; 84: 407-15.
42. Kahn CR, White MF. The insulin receptor and the molecular mechanism of insulin action. J Clin Invest 1988; 82: 1151-6.
43. Kanzaki M, Watson RT, Artemyev NO, Pessin JE. The trimeric GTP-binding protein (G(q)/G(11) alpha subunit is required for insulin-stimulated GLUT4 translocation in 3T3L1 adipocytes. J Biol Chem 2000; 275: 7167-75.
44. Usui I, Imamura T, Satoh H et al. GRK2 is an endogenous protein inhibitor of the insulin signaling pathway for glucose transport stimulation. Embo J 2004; 23; 2821-9.
45. Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 2005; 11: 952-8.
46. Usui I, Imamura T, Babendure JL et al. G protein-coupled receptor kinase 2 mediates endothelin-1-induced insulin resistance via the inhibition of both Galphaq/11 and insulin receptor substrate-1 pathways in 3T3-L1 adipocytes. Mol Endocrinol 2005; 19: 2760-8.
47. Shahid G, Hussain T. GRK2 negatively regulates glycogen synthesis in mouse liver FL83B cells. J Biol Chem 2007; 282: 20612-20.
48. Esposito DL, Li Y, Cama A, Quon MJ. Tyr(612) and Tyr(632) in human insulin receptor substrate-1 are important for full activation of insulin-stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose cells. Endocrinology 2001; 142: 2833-40.
49. Rui L, Aguirre V, Kim JK et al. Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J Clin Invest 2001; 107: 181-9.
50. Zheng Y, Zhang W, Pendleton E et al. Improved insulin sensitivity by calorie restriction is associated with reduction of ERK and p70S6K activities in the liver of obese Zucker rats. J Endocrinol 2009; 203: 337-47.
51. Ragheb R, Shanab GM, Medhat AM, Seoudi DM, Adeli K, Fantus IG. Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: evidence for PKC activation and oxidative stress-activated signaling pathways. Biochem Biophys Res Commun 2009; 389: 211-6.
52. Vinayagamoorthi R, Bobby Z, Sridhar MG. Antioxidants preserve redox balance and inhibit c-Jun-N-terminal kinase pathway while improving insulin signaling in fat-fed rats: evidence for the role of oxidative stress on IRS-1 serine phosphorylation and insulin resistance. J Endocrinol 2008; 197: 287-96.
53. Martins IJ, Hone E, Foster JK et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006; 11: 721-36.
54. Heininger K. A unifying hypothesis of Alzheimer's disease. III. Risk factors. Hum Psychopharmacol 2000; 15: 1-70.
55. Obrenovich ME, Smith MA, Siedlak SL et al. Overexpression of GRK2 in Alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. Neurotox Res 2006; 10: 43-56.
56. Iaccarino G, Barbato E, Cipolletta et al. Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. Eur Heart J 2005; 26: 1752-8.
57. Aliev G, Seyidova D, Neal ML et al. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann N Y Acad Sci 2002; 977: 45-64.
58. Aliev G, Smith MA, Seyidov D et al. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol 2002; 12: 21-35.
59. Nunomura A, Perry G, Aliev G et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60: 759-67.
60. Zhu X, Smith MA, Honda K et al. Vascular oxidative stress in Alzheimer disease. J Neurol Sci 2007; 257: 240-6.
61. Cobelens PM, Kavelaars A, Heijnen, CJ, Ribas C, Mayor F Jr, Penela P. Hydrogen peroxide impairs GRK2 translation via a calpain-dependent and cdk1-mediated pathway. Cell Signal 2007; 19: 269-77.
62. Garcia Soriano F, Virag L, Jagtap P et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001; 7: 108-13.
63. Freedman NJ, Ament AS, Oppermann, M, Stoffel RH, Exum ST, Lefkowitz R J. Phosphorylation and desensitization of human endothelin A and B receptors. Evidence for G protein-coupled receptor kinase specificity. J Biol Chem 1997; 272: 17734-43.
64. Neubauer SN. The failing heart--an engine out of fuel. Engl J Med 2007; 356: 1140-51.
65. Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest 1987; 79: 359-66.
66. Bing RJ, Siegel A, Ungar I, Gilbert M. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism. Am J Med 1954; 16: 504-15.
67. Lommi J, Kupari M, Yki-Jarvinen H. Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol 1998; 81: 45-50.
68. Taylor M, Wallhaus TR, Degrado TR et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in Patients with Congestive Heart Failure. Nucl Med 2001; 42: 55-62.
69. Neubauer S, Krahe T, Schindler R et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 1992; 86: 1810-8.
70. Peterson LR, Waggoner AD, Schechtman KB et al. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 2004; 43: 1399-404.
71. Mazumder PK, O'Neill BT, Roberts MW et al. Impaired cardiac efficiency and increased fatty acid oxidation in insulin-resistant ob/ob mouse hearts. Diabetes 2004; 53: 2366-74.
72. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000; 279: E1104-13.
73. Semeniuk LM, Kryski AJ, Severson DL. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol 2002; 283: H976-82.
74. Boudina S, Bugger H, Sena S. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 2009; 119: 1272-83.
75. Witteles RM, Tang WH, Jamali AH, Chu JW, Reaven GM, Fowler MB. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol 2004; 44: 78-81.
76. Kostis JB, Sanders M. The association of heart failure with insulin resistance and the development of type 2 diabetes. Am J Hypertens 2005; 18: 731-7.
77. Zucker IH. Novel mechanisms of sympathetic regulation in chronic heart failure. Hypertension 2006; 48: 1005-11.
78. Opie LH, Sack MN. Metabolic plasticity and the promotion of cardiac protection in ischemia and ischemic preconditioning. J Mol Cell Cardiol 2002; 34: 1077-89.
79. Bonita RE, Raake PW, Otis NJ et al. Dynamic changes in lymphocyte GRK2 levels in cardiac transplant patients: a biomarker for left ventricular function. Clin Transl Sci 2008; 3: 14-8.
80. Iaccarino G, Koch WJ. Transgenic mice targeting the heart unveil G protein-coupled receptor kinases as therapeutic targets. Assay Drug Dev Technol 2003; 1: 347-55.
81. Ciccarelli M, Chuprun JK, Rengo G et al. G protein-coupled receptor kinase 2 activity impairs cardiac glucose uptake and promotes insulin resistance after myocardial ischemia. Circulation 2011; 123: 1953-62.
82. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002; 277: 1531-7.